Tuesday, October 27, 2020 3:08:40 PM
Amber Tong
Editor
When the FDA slapped a rejection on Kala Pharma’s dry eye drug last August, the biotech’s execs promised investors that a third Phase III study — they had already started at that point — would reverse their fortune.
Today they made good on that promise, clinching an approval for Eysuvis, an ocular corticosteroid being positioned as a first-line, short term treatment of dry eye disease.
Boasting a technology invented by Bob Langer out of MIT, Eysuvis is a corticosteroid, loteprednol etabonate, delivered by mucus-penetrating particles. It promises to enhance penetration into target tissue on the ocular surface, achieving an effect quicker than systemic corticosteroids and stronger than over-the-counter eye drops.
Kala, with $159.1 million in cash, cash equivalents and short-term investments that it expects to last until Q3 of 2022, expects to launch the drug by year’s end pending some final touches on the salesforce (125 reps to start with) and manufacturing.
The top team, led by CEO Mark Iwicki, has repeatedly emphasized that the market is huge yet untapped, with just a few prescription drugs available in the category. One of them, Shire’s Xiidra, was bought by Novartis for $3.4 billion upfront.
Over 30 million people in the United States live with dry eye disease, of which over 17 million have already been diagnosed by an eye care professional.
Our market research suggests that 80% to 90% of these patients suffer from episodic flares rather than continuous symptoms, and feedback from eye care professionals suggest that these flares are – will be under-managed by current therapies.
In a note from September, Jefferies analyst Biren Amin wrote that steroids are commonly prescribed off-label for flares but risks of elevated intraocular pressure discourage non-corneal specialists from doing so.
Data from STRIDE3, the final Phase III study that finally satisfied regulators, suggested that Eysuvis induced a statistically significant improvement in ocular discomfort severity over placebo.
Doctors Amin spoke to “see the opportunity for it to be adopted by corneal specialists and should remove the barrier for non-corneal specialists to prescribe a steroid type treatment for DED flares.”
AUTHOR
Amber Tong
Editor
amber@endpointsnews.com
@AmberTongPW
Amber Tong on LinkedIn
https://endpts.com/once-rejected-kalas-dry-eye-drug-now-gains-entry-to-a-field-where-novartis-is-grooming-its-own-blockbuster/
Recent KALA News
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:19 PM
- KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 06:09:11 PM
- KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/19/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:04:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:03:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 01:22:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:05:17 PM
- KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/18/2023 08:04:57 PM
- KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/20/2023 08:01:00 PM
- KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/04/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 08:01:10 PM
- KALA BIO to Participate in Upcoming Investor Conferences in August • GlobeNewswire Inc. • 08/02/2023 08:01:00 PM
- Kala Pharmaceuticals Announces Name Change to KALA BIO • GlobeNewswire Inc. • 08/02/2023 12:00:00 PM
- Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/19/2023 08:01:00 PM
- Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/23/2023 08:01:00 PM
- Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 06/02/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM